SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc is seeing increased volatility as investors weigh the company's recent acquisition of World View and multiple defense contract wins, including counter-drone security for the 2026 FIFA World Cup, against concerns over potential future dilution from a proposed increase in authorized shares. The community remains deeply divided, with bulls highlighting the firm's strengthened competitive positioning and scaling revenue, while bears express skepticism regarding share count expansion and the stock's recent price performance.

Maulcoin

Maulcoin is surging in popularity as investors rally behind its community-driven, "no-rug" philosophy, with many holding strong in anticipation of further gains and potential airdrops. The community is actively coordinating to drive volume and increase social media visibility, framing the stock as an emerging contender against established meme coins.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp is a focal point for the trading community due to its status as a low-float SPAC, fueling speculative discussions about potential merger activity and the likelihood of a significant price surge. Investors are intensely debating the stock's volatility, with many monitoring for signs of a short squeeze or institutional movement as the company approaches critical merger and filing deadlines.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Markets are under pressure as U.S.-Iran peace talks in Pakistan concluded without a deal, fueling uncertainty over the status of the Strait of Hormuz and energy supplies. While some community members are bracing for a volatile opening based on geopolitical risks, others remain skeptical, citing a pattern of tactical market manipulation and anticipation of further government commentary.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors grapple with heightened geopolitical uncertainty following the collapse of high-stakes peace negotiations with Iran. Market participants are actively debating the potential economic impact of these failed talks and the broader instability surrounding the current administration's foreign policy.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as shareholders organize to challenge the company's planned sale to Garda Therapeutics, citing deep undervaluation of the Rolvedon asset and concerns over the board's fiduciary duties. The community is actively discussing potential legal injunctions, lobbying top institutional holders, and questioning the deal structure, while sentiment remains mixed between activist opposition and skepticism regarding the board's decision-making.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Petroleo Brasileiro is trending as investors weigh strong production milestones and lucrative dividend yields against ongoing geopolitical volatility and shifts in regional energy policy. The community is actively debating the stock's long-term valuation in relation to global oil benchmarks and the potential impact of currency fluctuations on its ADR performance.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing intense market volatility driven by stalled peace negotiations between the U.S. and Iran, with traders debating whether the asset will break toward higher resistance or face a sharp correction due to escalating geopolitical tensions. The community remains deeply divided, with bulls pointing to institutional accumulation and ETF inflows as signs of structural strength, while bears warn that continued uncertainty in the Strait of Hormuz and a lack of diplomatic progress create a high-risk environment for a potential sell-off.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors weigh its critical role in the global AI semiconductor supply chain against heightened geopolitical risks, particularly the potential for supply chain disruptions in the Strait of Hormuz. The community is actively debating the company's valuation versus its strategic 'bottleneck' status as a monopoly for advanced lithography equipment.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is facing significant downward pressure following its latest investor day, where the company outlined a long-term roadmap to profitability by the end of the decade despite continued cash burn and production delays. While some investors see potential in the newly unveiled midsize EV platform and robotaxi initiatives, the community remains heavily divided between those betting on a major short squeeze and those increasingly skeptical of the company's ability to survive without further dilution.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why GSK (GSK) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

<ul class="summary-bullets"><li>FDA approved leucovorin in the treatment of cerebral folate transport deficiency last month but not in autism.</li><li>Leucovorin garnered attention in the latter half of 2025 after Donald Trump and his administration promoted it as an "exciting" and “promising” therapeutic for autism.</li><li>According to research published in The Lancet, outpatient leucovorin prescriptions for children aged 5–17 years increased by 71% following the press briefing in September.</li></ul>UK drugmaker GSK Plc (GSK) has withdrawn its application for the drug leucovorin calcium touted by President Trump as a potential treatment for autism.GSK asked the U.S. Food and Drug Administration to pull its application for leucovorin calcium because it no longer markets the medicine, a filing on the FDA website shows.The news was first reported by The Wall Street Journal. &nbsp;<h2 class="st-heading-2">Leucovorin Approval And Claims</h2>According <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/gsk-nixes-application-for-drug-touted-by-trump-for-autism-4d5bdead">to </a>WSJ, GSK said in September that it would submit an application for the drug in the treatment of cerebral folate transport deficiency following a request from the FDA. The agency approved the drug for the condition last month, but not for autism. The company, however, hasn’t sold the drug since 1999, the report noted. &nbsp;A GSK spokesperson reportedly told the newspaper that the company never intended to sell the drug again. Meanwhile, a spokesperson for the U.S. Department of Health and Human Services told the paper that GSK’s decision has no bearing on generic versions of the drug for patients with cerebral folate deficiency.Leucovorin garnered attention in the latter half of 2025 after Donald Trump and his administration promoted it as an "exciting" and “promising” therapeutic for autism. According to <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00243-6/fulltext">research</a> published in The Lancet, outpatient leucovorin prescriptions for children aged 5–17 years increased by 71% following the press briefing in September where Trump made his claims with Robert F Kennedy Jr.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around GSK stock stayed within the ‘bearish’ territory, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/GSK">GSK stock</a> has gained 69% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-heads-for-8th-straight-week-of-price-decline/cZJWlLZRIsZ">TSLA Stock Heads For 8th Straight Week Of Price Decline — What’s Driving The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Reportedly Pulls Application For Drug Touted By Trump As Potential Treatment For Autism

According to a report from the Wall Street Journal on Thursday, GSK asked the FDA to pull its application for leucovorin calcium because it no longer markets the medicine.

Equity

GSK plc (LON:GSK) Receives Consensus Recommendation of "Hold" from Analysts

Shares of GSK plc (LON:GSK - Get Free Report) have been given a consensus recommendation of "Hold" by the seven brokerages that are presently covering the firm, Marketbeat.com reports. One research...

GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermatitis study misses main goal.read more...

GSK (LON:GSK) Given "Buy" Rating at Jefferies Financial Group

Jefferies Financial Group restated a "buy" rating and issued a GBX 2,450 price objective on shares of GSK in a research report on Thursday...

Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report

According to a Bloomberg report, Trump may impose 100% tariffs on drugmakers without pricing deals, as part of a broader push to lower drug costs.read more...

GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Analysts

Shares of GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) have received an average recommendation of "Reduce" from the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, seven ha...

Bristol Myers Squibb adding 3 medications on TrumpRx

EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned.The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price.The Princeton, New Jersey-based company's drug Sotyktu retails for...

GSK Sets Up Late-Stage Readouts: Chronic Cough Phase 3 Data Near, Hep B Filing on Track

GSK (NYSE:GSK) respiratory, immunology and inflammation R&D head Kaivan Khavandi said the company is positioning several late-stage programs around clear unmet need and what he described as better "target trait pairing," highlighting upcoming chronic cough data, planned hepatitis B regulatory st...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Current Price	$58.21
Prev Close	$58.36
Open	$59.05
Dividend Yield	3.56%
50-Day Moving Average	$56.22
Beta	0.29
Avg. Volume	4.75M
PE Ratio	15.67

52-Week High	$61.70
52-Week Low	$34.73
Market Capitalization	$116.32B
EPS (Annual)	$3.72
Price to Book	5.30
Revenue Per Employee	$644,088.53

GSK
Glaxosmithkline plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GSK News

GSKGlaxosmithkline plc - ADR